FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996985265> ?p ?o ?g. }

• W1996985265 endingPage "450" @default.
• W1996985265 startingPage "441" @default.
• W1996985265 abstract "New targeted therapeutics approved for metastatic renal cell carcinoma (mRCC) offer multiple options in each line of therapy; however, there are few prospective data beyond the first-line settings, and overall comparative effectiveness data are limited. In the targeted therapy era, progression-free survival (PFS) has been the most common regulatory end point for demonstrating the benefit of new therapies.Drawing on a joint community-academic retrospective mRCC registry, we analyzed all patients who had undergone at least 1 line of systemic therapy (N = 325) for PFS. Patients were grouped according to treatment choice (sorafenib, sunitinib, temsirolimus, everolimus, and other) for up to 3 lines of therapy. PFS by treatment choice and line of therapy was evaluated using Kaplan-Meier and Cox regression analyses.PFS was longest in patients treated with sunitinib in the first and second lines of therapy. First-line PFS for sorafenib, sunitinib, temsirolimus, everolimus, and other was 6.9, 8.9, 4.2, not analyzed (too few patients), and 10.8 months, respectively. Second-line PFS was 4.6, 7.0, 3.2, 3.8, and 4.1 months, respectively. Third-line PFS was 4.5, 4.6, 9.9, 4.2, and 2.9, months, respectively. The risk of progression in patients treated with temsirolimus was about twice that of patients treated with sunitinib in the first and second lines of therapy.Patients treated with sunitinib had the longest PFS in the first and second lines of therapy. PFS from practice-based data appear consistent with trial-based expectations; however, practice variation was still evident." @default.
• W1996985265 created "2016-06-24" @default.
• W1996985265 creator A5000997350 @default.
• W1996985265 creator A5006742120 @default.
• W1996985265 creator A5008327646 @default.
• W1996985265 creator A5020223699 @default.
• W1996985265 creator A5040097028 @default.
• W1996985265 creator A5064227174 @default.
• W1996985265 creator A5075569504 @default.
• W1996985265 creator A5085797478 @default.
• W1996985265 date "2013-12-01" @default.
• W1996985265 modified "2023-10-18" @default.
• W1996985265 title "“Real World” Treatment of Metastatic Renal Cell Carcinoma in a Joint Community-Academic Cohort: Progression-Free Survival Over Three Lines of Therapy" @default.
• W1996985265 cites W1568494625 @default.
• W1996985265 cites W1999966467 @default.
• W1996985265 cites W2015054022 @default.
• W1996985265 cites W2023952988 @default.
• W1996985265 cites W2054972715 @default.
• W1996985265 cites W2083513799 @default.
• W1996985265 cites W2099088585 @default.
• W1996985265 cites W2099752220 @default.
• W1996985265 cites W2115005218 @default.
• W1996985265 cites W2118677643 @default.
• W1996985265 cites W2121274101 @default.
• W1996985265 cites W2123784879 @default.
• W1996985265 cites W2138129102 @default.
• W1996985265 cites W2143813821 @default.
• W1996985265 cites W2147864956 @default.
• W1996985265 cites W2149456801 @default.
• W1996985265 cites W2153867442 @default.
• W1996985265 cites W2160120519 @default.
• W1996985265 cites W2160476851 @default.
• W1996985265 cites W2162424705 @default.
• W1996985265 cites W2165948908 @default.
• W1996985265 cites W2414641360 @default.
• W1996985265 doi "https://doi.org/10.1016/j.clgc.2013.05.002" @default.
• W1996985265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23856102" @default.
• W1996985265 hasPublicationYear "2013" @default.
• W1996985265 type Work @default.
• W1996985265 sameAs 1996985265 @default.
• W1996985265 citedByCount "24" @default.
• W1996985265 countsByYear W19969852652014 @default.
• W1996985265 countsByYear W19969852652015 @default.
• W1996985265 countsByYear W19969852652016 @default.
• W1996985265 countsByYear W19969852652017 @default.
• W1996985265 countsByYear W19969852652018 @default.
• W1996985265 countsByYear W19969852652019 @default.
• W1996985265 countsByYear W19969852652020 @default.
• W1996985265 countsByYear W19969852652021 @default.
• W1996985265 countsByYear W19969852652023 @default.
• W1996985265 crossrefType "journal-article" @default.
• W1996985265 hasAuthorship W1996985265A5000997350 @default.
• W1996985265 hasAuthorship W1996985265A5006742120 @default.
• W1996985265 hasAuthorship W1996985265A5008327646 @default.
• W1996985265 hasAuthorship W1996985265A5020223699 @default.
• W1996985265 hasAuthorship W1996985265A5040097028 @default.
• W1996985265 hasAuthorship W1996985265A5064227174 @default.
• W1996985265 hasAuthorship W1996985265A5075569504 @default.
• W1996985265 hasAuthorship W1996985265A5085797478 @default.
• W1996985265 hasConcept C121608353 @default.
• W1996985265 hasConcept C126322002 @default.
• W1996985265 hasConcept C143998085 @default.
• W1996985265 hasConcept C183713625 @default.
• W1996985265 hasConcept C185592680 @default.
• W1996985265 hasConcept C185926286 @default.
• W1996985265 hasConcept C190283241 @default.
• W1996985265 hasConcept C2776820818 @default.
• W1996985265 hasConcept C2776999253 @default.
• W1996985265 hasConcept C2777472916 @default.
• W1996985265 hasConcept C2778019345 @default.
• W1996985265 hasConcept C2778695046 @default.
• W1996985265 hasConcept C2779490328 @default.
• W1996985265 hasConcept C2779699572 @default.
• W1996985265 hasConcept C2780739268 @default.
• W1996985265 hasConcept C2781230642 @default.
• W1996985265 hasConcept C3019894029 @default.
• W1996985265 hasConcept C530470458 @default.
• W1996985265 hasConcept C55493867 @default.
• W1996985265 hasConcept C71924100 @default.
• W1996985265 hasConcept C86554907 @default.
• W1996985265 hasConceptScore W1996985265C121608353 @default.
• W1996985265 hasConceptScore W1996985265C126322002 @default.
• W1996985265 hasConceptScore W1996985265C143998085 @default.
• W1996985265 hasConceptScore W1996985265C183713625 @default.
• W1996985265 hasConceptScore W1996985265C185592680 @default.
• W1996985265 hasConceptScore W1996985265C185926286 @default.
• W1996985265 hasConceptScore W1996985265C190283241 @default.
• W1996985265 hasConceptScore W1996985265C2776820818 @default.
• W1996985265 hasConceptScore W1996985265C2776999253 @default.
• W1996985265 hasConceptScore W1996985265C2777472916 @default.
• W1996985265 hasConceptScore W1996985265C2778019345 @default.
• W1996985265 hasConceptScore W1996985265C2778695046 @default.
• W1996985265 hasConceptScore W1996985265C2779490328 @default.
• W1996985265 hasConceptScore W1996985265C2779699572 @default.
• W1996985265 hasConceptScore W1996985265C2780739268 @default.
• W1996985265 hasConceptScore W1996985265C2781230642 @default.
• W1996985265 hasConceptScore W1996985265C3019894029 @default.
• W1996985265 hasConceptScore W1996985265C530470458 @default.

• next